CN109847946B - Application of medicament in flotation decalcification of magnesite - Google Patents
Application of medicament in flotation decalcification of magnesite Download PDFInfo
- Publication number
- CN109847946B CN109847946B CN201811625089.5A CN201811625089A CN109847946B CN 109847946 B CN109847946 B CN 109847946B CN 201811625089 A CN201811625089 A CN 201811625089A CN 109847946 B CN109847946 B CN 109847946B
- Authority
- CN
- China
- Prior art keywords
- magnesite
- flotation
- pulp
- decalcification
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03B—SEPARATING SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS
- B03B1/00—Conditioning for facilitating separation by altering physical properties of the matter to be treated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03B—SEPARATING SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS
- B03B1/00—Conditioning for facilitating separation by altering physical properties of the matter to be treated
- B03B1/04—Conditioning for facilitating separation by altering physical properties of the matter to be treated by additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03D—FLOTATION; DIFFERENTIAL SEDIMENTATION
- B03D1/00—Flotation
- B03D1/001—Flotation agents
- B03D1/002—Inorganic compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03D—FLOTATION; DIFFERENTIAL SEDIMENTATION
- B03D1/00—Flotation
- B03D1/001—Flotation agents
- B03D1/004—Organic compounds
- B03D1/01—Organic compounds containing nitrogen
Landscapes
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of a medicament in flotation decalcification of magnesite belongs to the technical field of magnesite beneficiation and purification processes. The application of the agent in flotation decalcification of magnesite is to use an inhibitor BAPTA in the flotation decalcification process of magnesite. Specifically, the method comprises the following steps: crushing and ball-milling high-calcium low-grade magnesite to obtain magnesite powder; putting magnesite powder into flotation equipment, adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, uniformly mixing, carrying out size mixing, adding NaOH into the magnesite pulp at room temperature, adjusting the pH value to 10-12, adding a collecting agent sodium oleate, uniformly stirring, and carrying out direct flotation roughing to obtain the low-calcium magnesite concentrate. The added inhibitor BAPTA has flotability difference to magnesite and impurity mineral dolomite in the magnesite, removes calcium mineral in the magnesite, improves the quality of the magnesite, and provides a new medicament for mineral separation and decalcification of high-calcium low-grade magnesite.
Description
Technical Field
The invention relates to the technical field of magnesite beneficiation and purification processes, in particular to application of a medicament in magnesite flotation decalcification.
Background
In the process of magnesite beneficiation and purification, the key for improving the quality of magnesite is to reduce the CaO content. CaO in magnesite is mainly contained in impurity mineral dolomite (CaMg (CO)3)2) In (1). However, because dolomite and magnesite belong to carbonate gangue minerals, the dolomite and magnesite have the same molecular structure and similar chemical properties, and the embedded granularity of other minerals is fine, the dissolution of the magnesite and the dolomite minerals in the flotation process causes a large amount of magnesium and calcium ions to be dissolved into ore pulp, and because the physical and chemical properties of the calcium and magnesium ions are similar, the magnesium carbonate, the calcium carbonate and the like are easy to dissolve under certain conditionsSurface conversion occurs, so that the surface properties of magnesite and dolomite converge, and the difficulty of flotation separation is increased. Therefore, it is imperative to find a chelating agent that is highly selective for calcium ions to eliminate the effect of calcium ions in the magnesite flotation process.
Disclosure of Invention
The invention aims to provide an application of a medicament in magnesite flotation decalcification, which is to add an inhibitor BAPTA in the magnesite flotation decalcification process, remove calcium minerals in magnesite according to floatability difference of impurity mineral dolomite in the magnesite and the magnesite under the dosage of different inhibitors BAPTA (1, 2-bis (o-aminophenoxy) ethane-N, N, N ', N' -tetraacetic acid), improve the quality of the magnesite, and provide a new medicament for mineral separation and decalcification of high-calcium low-grade magnesite.
The invention relates to an application of a medicament in magnesite flotation decalcification, which is to apply an inhibitor BAPTA in a magnesite flotation decalcification process.
Furthermore, the application of the medicament in magnesite flotation decalcification is to use the inhibitor BAPTA in the size mixing process in the magnesite flotation decalcification process so as to prepare magnesite pulp.
Furthermore, the application of the medicament in flotation decalcification of magnesite is to dissolve an inhibitor BAPTA in dimethyl sulfoxide to prepare an inhibitor BAPTA dimethyl sulfoxide solution with the molar concentration of 1.25-3.25 g/L for use.
The agent is used for a magnesite flotation decalcification process, and specifically comprises the following steps:
step 1: ore grinding
Crushing and ball-milling high-calcium low-grade magnesite to obtain magnesite powder; wherein, in the magnesite powder, the magnesite powder with the particle size of less than 74 μm accounts for 70-90% of the total magnesite powder;
step 2: size mixing
Putting magnesite powder into flotation equipment, adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, uniformly mixing, and carrying out size mixing to obtain magnesite pulp; wherein the mass concentration of the magnesite powder in the magnesite pulp is 20-40%; the molar concentration of the inhibitor BAPTA dimethyl sulfoxide solution is 1.25-3.25 g/L; according to the solid-liquid ratio, the inhibitor BAPTA: magnesite pulp (30-60) mg: 1L;
and step 3: direct flotation decalcification
Adding NaOH into the magnesite pulp at room temperature, adjusting the pH value to 10-12, and uniformly stirring to obtain the magnesite pulp with the pH value of 10-12;
adding a collecting agent sodium oleate into magnesite pulp with the pH value of 10-12, uniformly stirring, and then carrying out direct flotation roughing to obtain low-calcium magnesite concentrate; wherein, according to the solid-to-liquid ratio, the collecting agent sodium oleate in the collecting agent sodium oleate water solution: magnesite pulp (100-140) mg: 1L of the compound.
In the step 1, the main components and all the components of the high-calcium low-grade magnesite comprise 25-35.5 wt% of MgO, 18-25 wt% of CaO and SiO20 to 0.5%.
In the step 2, the flotation equipment is preferably a hanging-groove type flotation machine, and the rotating speed is 1600-1900 rpm.
In the step 2, the dosage of the inhibitor BAPTA accounts for the magnesite pulp, and is preferably 40 mg/L.
In the step 3, the NaOH is preferably NaOH aqueous solution with the mass fraction of 1-5%.
In the step 3, the mixture is uniformly stirred, the stirring speed is 1600-1900 rpm, and the stirring time is 2-5 min.
In the step 3, the pH value is preferably 11.
In the step 3, the rotation speed of the direct flotation equipment for the direct flotation roughing is 1600-1900 rpm, preferably 1800rpm, and the direct flotation time is preferably 3-5 min.
In the step 3, the collecting agent sodium oleate is preferably a sodium oleate water solution with the molar concentration of 0.01-0.05 mol/L.
In the step 3, the preferable usage amount of the collecting agent sodium oleate in the magnesite pulp is 120 mg/L.
In the step 3, after adding the collecting agent sodium oleate, adding a foaming agent, uniformly stirring, and finally performing direct flotation roughing, wherein the foaming agent is preferably No. 2 oil, and the ratio of solid to liquid is No. 2 oil: magnesite pulp (4-6) mg: 1L of the compound.
In the step 3, the main components and all the components of the low-calcium magnesite concentrate are MgO47.5-48.5 wt%, and SiO2≤0.3％，CaO≤0.6％。
The agent is used in the flotation decalcification process of magnesite, the recovery rate of the low-calcium magnesite concentrate is 70-85% by weight, and the recovery rate of MgO in the low-calcium magnesite concentrate is 65-75% by weight.
Compared with the prior art, the application of the medicament in flotation decalcification of magnesite has the following beneficial effects:
1. the invention develops the use of the novel inhibitor BAPTA, and the novel inhibitor BAPTA has strong selective inhibition on calcium-containing minerals, thereby shortening and simplifying the flotation decalcification process, leading the flotation process to operate more stably and the operation to be simpler and more convenient, and leading the novel inhibitor BAPTA to have more environmental protection compared with other chemical inhibitors. Finally, magnesite concentrate with MgO grade higher than 47% and recovery rate of 65-85% can be obtained.
2. Compared with the prior art, the method has the advantages that the processed ore has low grade, and the content of CaO in the raw ore is high; the obtained magnesite concentrate can reach the special grade standard (YB 321-81) of metallurgical industry, namely MgO is more than or equal to 47.00 percent and SiO2≤0.30％、CaO≤0.8％。
3. The inhibitor BAPTA (1, 2-bis (o-aminophenoxy) ethane-N, N, N ', N' -tetraacetic acid) is a chelating agent with extremely strong calcium selectivity, is mainly used for monitoring calcium ions in cells biologically, and is used as a dolomite inhibitor in the magnesite flotation decalcification process because BAPTA can generate hydrophilic chelate with the calcium ions, so that the influence of the inhibitor BAPTA on the flotation of magnesite and dolomite is different, and a new inhibitor is provided for the low-grade magnesite beneficiation decalcification.
Drawings
Fig. 1 is a process flow diagram of the application of the agent in embodiment 1 of the invention in flotation decalcification of magnesite.
Figure 2 is an XRD pattern of the raw material magnesite according to the present invention.
Detailed Description
The present invention will be described in further detail with reference to examples.
In the following examples, the high-calcium low-grade magnesite used is Liaoning widow water tunnel ditch magnesite, and the element components of the high-calcium low-grade magnesite are analyzed by an X-ray fluorescence spectrum analyzer, and the main components are as follows by weight percent: 33.58% of MgO and SiO20.27%, CaO 15.17%, and the balance CO2And unavoidable impurities; the XRD pattern is shown in FIG. 2. The used inhibitor BAPTA is analytically pure, the collecting agent sodium oleate is chemically pure, and the pH value regulator sodium hydroxide is analytically pure. The BAPTA medicament used in the test is dissolved and prepared by dimethyl sulfoxide, and the other reagents are prepared into aqueous solutions with corresponding concentrations by deionized water for later use.
Example 1
The application of the medicament in flotation decalcification of magnesite is shown in a schematic process flow diagram in figure 1 and comprises the following steps:
step 1: ore grinding
Crushing and ball-milling a high-calcium low-grade magnesite raw material to obtain magnesite powder; wherein, in the magnesite powder, the magnesite powder with the grain size less than 74 μm accounts for 70% of the total magnesite powder;
step 2: size mixing
Putting magnesite powder with the grain size of less than 74 mu m and accounting for 70% of the total magnesite powder mass into a hanging-tank type flotation machine, and adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, wherein the inhibitor BAPTA: magnesite pulp is 30 mg: 1L, uniformly mixing, and performing size mixing to obtain magnesite pulp; wherein the mass concentration of magnesite in the magnesite pulp is 20%; the molar concentration of the inhibitor BAPTA dimethyl sulfoxide solution is 1.25 g/L;
and step 3: direct flotation decalcification
At room temperature, firstly adding a NaOH aqueous solution with the mass fraction of 3% into the magnesite pulp, adjusting the pH value to 11, and then stirring for 2min until the pulp is uniform to obtain the magnesite pulp with the pH value of 11;
adding a collecting agent sodium oleate aqueous solution with the molar concentration of 0.05mol/L into magnesite pulp with the pH value of 11, wherein the adding amount of sodium oleate accounts for 100mg/L of the magnesite pulp, stirring for 2min, then adding foaming agent No. 2 oil, the adding amount of No. 2 oil accounts for 5mg/L of the magnesite pulp, stirring for 2min, and finally carrying out 3min positive flotation roughing to obtain the low-calcium magnesite concentrate. In the test process, the rotating speed of the flotation machine is set to be 1800 r/min.
In this example, the main components of the low-calcium magnesite concentrate are 47.23% by weight of MgO and SiO20.25 percent of CaO and 0.59 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 66.25% of the total weight of the MgO in the raw materials.
Example 2
The application of the medicament in flotation decalcification of magnesite comprises the following steps:
step 1: ore grinding
Crushing and ball-milling a high-calcium low-grade magnesite raw material to obtain magnesite powder; wherein, in the magnesite powder, the magnesite powder with the grain size less than 74 μm accounts for 80% of the total magnesite powder;
step 2: size mixing
Putting magnesite powder with the grain size of less than 74 mu m and accounting for 80 percent of the total magnesite powder mass into a hanging-tank type flotation machine, and adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, wherein the inhibitor BAPTA: magnesite pulp of 40 mg: 1L, uniformly mixing, and performing size mixing to obtain magnesite pulp; wherein the mass concentration of magnesite in the magnesite pulp is 25%; the molar concentration of the inhibitor BAPTA dimethyl sulfoxide solution is 3.25 g/L;
and step 3: direct flotation decalcification
At room temperature, firstly adding a NaOH aqueous solution with the mass fraction of 3% into the magnesite pulp, adjusting the pH value to 12, and then stirring for 2min until the pulp is uniform to obtain the magnesite pulp with the pH value of 12;
adding a collecting agent sodium oleate aqueous solution with the molar concentration of 0.06mol/L into magnesite pulp with the pH value of 12, wherein the adding amount of sodium oleate accounts for 110mg/L of the magnesite pulp, stirring for 2min, then adding foaming agent No. 2 oil, the adding amount of No. 2 oil accounts for 6mg/L of the magnesite pulp, stirring for 2min, and finally carrying out 3min positive flotation roughing to obtain the low-calcium magnesite concentrate. In the test process, the rotating speed of the flotation machine is set to 1700 r/min.
In this example, the main components of the low-calcium magnesite concentrate are 48.13% by weight of MgO and SiO20.14 percent of CaO and 0.61 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 70.25% of the total weight of the MgO in the raw materials.
Example 3
The application of the medicament in flotation decalcification of magnesite comprises the following steps:
step 1: ore grinding
Crushing and ball-milling a high-calcium low-grade magnesite raw material to obtain magnesite powder; wherein, in the magnesite powder, the magnesite powder with the grain size less than 74 μm accounts for 80% of the total magnesite powder;
step 2: size mixing
Putting magnesite powder with the grain size of less than 74 mu m and accounting for 80 percent of the total magnesite powder mass into a hanging-tank type flotation machine, and adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, wherein the inhibitor BAPTA: magnesite pulp is 50 mg: 1L, uniformly mixing, and performing size mixing to obtain magnesite pulp; wherein the mass concentration of magnesite in the magnesite pulp is 30 percent; the molar concentration of the inhibitor BAPTA dimethyl sulfoxide solution is 2.5 g/L;
and step 3: direct flotation decalcification
At room temperature, firstly adding a NaOH aqueous solution with the mass fraction of 4% into the magnesite pulp, adjusting the pH value to 10, and then stirring for 2min until the pulp is uniform to obtain the magnesite pulp with the pH value of 10;
adding a collecting agent sodium oleate aqueous solution with the molar concentration of 0.06mol/L into magnesite pulp with the pH value of 10, wherein the adding amount of sodium oleate accounts for 120mg/L of the magnesite pulp, stirring for 2min, then adding foaming agent No. 2 oil, the adding amount of No. 2 oil accounts for 4mg/L of the magnesite pulp, stirring for 2min, and finally carrying out 3min positive flotation roughing to obtain the low-calcium magnesite concentrate. In the test process, the rotating speed of the flotation machine is set to 1600 r/min.
In this example, the main components of the low-calcium magnesite concentrate are 47.73% by weight of MgO and SiO20.22 percent of CaO and 0.19 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 61.25 percent of the total weight of the MgO in the raw materials.
Example 4
The application of the medicament in flotation decalcification of magnesite comprises the following steps:
step 1: ore grinding
Crushing and ball-milling a high-calcium low-grade magnesite raw material to obtain magnesite powder; wherein, in the magnesite powder, the magnesite powder with the grain size less than 74 μm accounts for 90% of the total magnesite powder;
step 2: size mixing
Putting magnesite powder with the grain size of less than 74 mu m and accounting for 90 percent of the total magnesite powder mass into a hanging-tank type flotation machine, and adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, wherein the inhibitor BAPTA: magnesite pulp 60 mg: 1L, uniformly mixing, and performing size mixing to obtain magnesite pulp; wherein the mass concentration of magnesite in the magnesite pulp is 35 percent; the molar concentration of the inhibitor BAPTA dimethyl sulfoxide solution is 2.0 g/L;
and step 3: direct flotation decalcification
At room temperature, firstly adding a NaOH aqueous solution with the mass fraction of 3% into the magnesite pulp, adjusting the pH value to 11, and then stirring for 2min until the pulp is uniform to obtain the magnesite pulp with the pH value of 11;
adding a collecting agent sodium oleate aqueous solution with the molar concentration of 0.05mol/L into magnesite pulp with the pH value of 11, wherein the adding amount of sodium oleate accounts for 130mg/L of the magnesite pulp, stirring for 2min, then adding foaming agent No. 2 oil, the adding amount of No. 2 oil accounts for 4mg/L of the magnesite pulp, stirring for 2min, and finally carrying out 3min positive flotation roughing to obtain the low-calcium magnesite concentrate. In the test process, the rotation speed of the flotation machine is set to be 1900 r/min.
In the present embodiment, the first and second electrodes are,the main components of the low-calcium magnesite concentrate comprise 48.05 percent of MgO and 48.05 percent of SiO in percentage by weight20.25 percent of CaO and 0.39 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 73.69% of the total weight of the MgO in the raw materials.
Example 5
The application of the medicament in flotation decalcification of magnesite is the same as that in example 1, the difference is that the solid-liquid ratio of the inhibitor BAPTA: magnesite pulp of 40 mg: 1L, the main components of the obtained low-calcium magnesite concentrate comprise 47.23 percent of MgO and SiO in percentage by weight20.13 percent of CaO and 0.59 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 68.15% of the total weight of the MgO in the raw materials.
Example 6
The application of the medicament in flotation decalcification of magnesite is the same as that in example 1, the difference is that the solid-liquid ratio of the inhibitor BAPTA: magnesite pulp is 50 mg: 1L, the main components of the obtained low-calcium magnesite concentrate comprise 48.23 percent of MgO and 48.23 percent of SiO20.21 percent of CaO and 0.47 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 69.25 percent of the total weight of the MgO in the raw materials.
Example 7
The application of the medicament in flotation decalcification of magnesite is the same as that in example 1, the difference is that the solid-liquid ratio of the inhibitor BAPTA: magnesite pulp 60 mg: 1L, the main components of the obtained low-calcium magnesite concentrate comprise 48.61 percent of MgO and 48.61 percent of SiO in percentage by weight20.21 percent of CaO and 0.27 percent of CaO; the MgO in the low-calcium magnesite concentrate accounts for 76.26 percent of the total weight of the MgO in the raw materials.
Claims (10)
1. The application of the medicament in flotation decalcification of magnesite is characterized in that an inhibitor BAPTA is used in the flotation decalcification process of magnesite; the application process comprises the following steps:
and (3) size mixing: dissolving an inhibitor BAPTA in dimethyl sulfoxide to prepare an inhibitor BAPTA dimethyl sulfoxide solution with the molar concentration of 1.25-3.25 g/L;
putting magnesite powder into flotation equipment, adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, uniformly mixing, and carrying out size mixing to obtain magnesite pulp, wherein the mass concentration of the magnesite powder in the magnesite pulp is 20 ~ 40%, and the inhibitor BAPTA: magnesite pulp = (30 ~ 60) mg: 1L in a solid-to-liquid ratio;
a direct flotation decalcification process, namely adding NaOH into the magnesite pulp at room temperature, adjusting the pH value to 10 ~ 12, and uniformly stirring to obtain the magnesite pulp with the pH value of 10 ~ 12;
adding a collecting agent sodium oleate into magnesite pulp with the pH value of 10 ~ 12, uniformly stirring, and then carrying out direct flotation and rough separation to obtain low-calcium magnesite concentrate, wherein the collecting agent sodium oleate in a collecting agent sodium oleate aqueous solution is that the magnesite pulp is not less than (100 ~ 140) mg: 1L according to a solid-to-liquid ratio.
2. The use of the agent according to claim 1 in magnesite flotation decalcification, wherein the agent is used in magnesite flotation decalcification process, and specifically comprises the following steps:
step 1: ore grinding
Crushing and ball-milling high-calcium low-grade magnesite to obtain magnesite powder, wherein the magnesite powder with the particle size of less than 74 mu m accounts for 70 ~ 90% of the total magnesite powder;
step 2: size mixing
Putting magnesite powder into flotation equipment, adding deionized water and an inhibitor BAPTA dimethyl sulfoxide solution, uniformly mixing, and carrying out size mixing to obtain magnesite pulp, wherein the mass concentration of the magnesite powder in the magnesite pulp is 20 ~ 40%, the molar concentration of the inhibitor BAPTA dimethyl sulfoxide solution is 1.25 ~ 3.25.25 g/L, and the mass ratio of the inhibitor BAPTA to the magnesite pulp is = (30 ~ 60) mg: 1L;
and step 3: direct flotation decalcification
At room temperature, adding NaOH into the magnesite pulp, adjusting the pH value to 10 ~ 12, and uniformly stirring to obtain magnesite pulp with the pH value of 10 ~ 12;
adding a collecting agent sodium oleate into magnesite pulp with the pH value of 10 ~ 12, uniformly stirring, and then carrying out direct flotation and rough separation to obtain low-calcium magnesite concentrate, wherein the collecting agent sodium oleate in a collecting agent sodium oleate aqueous solution is that the magnesite pulp is not less than (100 ~ 140) mg: 1L according to a solid-to-liquid ratio.
3. The use of the agent of claim 2 in flotation decalcification of magnesite, wherein in step 1, the main component and individual components of the high-calcium low-grade magnesite are 25% 25 ~ 35.5.5% by weight of MgO, 18% 18 ~ 25% by weight of CaO, and SiO, respectively20 ~ 0.5.5%.
4. The use of the agent according to claim 2 in the flotation decalcification of magnesite, wherein in step 2 the flotation equipment is a hanging-tank flotation machine operating at 1600 ~ 1900 rpm.
5. The application of the agent in magnesite flotation decalcification according to claim 2, wherein in step 3, the NaOH is a 1 ~% NaOH aqueous solution by mass fraction, the stirring is uniform, the stirring speed is 1600 ~ rpm, and the stirring time is 2 ~ min.
6. The use of the agent of claim 2 in magnesite flotation decalcification, wherein in step 3, the direct flotation roughens, the rotation speed of the direct flotation equipment is 1600 ~ 1900rpm, and the direct flotation time is 3 ~ 5 min.
7. The use of the pharmaceutical agent of claim 2 in flotation decalcification of magnesite, wherein in step 3, the collecting agent sodium oleate is an aqueous solution of sodium oleate with a molarity of 0.01 ~ 0.05.05 mol/L.
8. The application of the agent in magnesite flotation decalcification according to claim 2, wherein in step 3, after adding sodium oleate serving as a collecting agent, a foaming agent is added, the mixture is uniformly stirred, and finally, direct flotation roughing is performed, wherein the foaming agent is No. 2 oil, and the ratio of No. 2 oil to magnesite pulp = (4 ~ 6) mg: 1L in terms of solid-to-liquid ratio.
9. The pharmaceutical preparation of claim 2The application of magnesite flotation decalcification is characterized in that in the step 3, the main components and all the components of the low-calcium magnesite concentrate are 47.5 percent of MgO47.5 ~ 48.5.5 percent by weight and SiO2≤0.3%，CaO≤0.6%。
10. The use of the agent of claim 1 in flotation decalcification of magnesite, wherein the agent is used in a process for flotation decalcification of magnesite, the recovery of low-calcium magnesite concentrate is 70 ~ 85% by weight, and the recovery of MgO in low-calcium magnesite concentrate is 65 ~ 75% by weight.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811625089.5A CN109847946B (en) | 2018-12-28 | 2018-12-28 | Application of medicament in flotation decalcification of magnesite |
| PCT/CN2019/070183 WO2020133557A1 (en) | 2018-12-28 | 2019-01-03 | Use of reagent in flotation decalcification of magnesite |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811625089.5A CN109847946B (en) | 2018-12-28 | 2018-12-28 | Application of medicament in flotation decalcification of magnesite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109847946A CN109847946A (en) | 2019-06-07 |
| CN109847946B true CN109847946B (en) | 2019-12-24 |
Family
ID=66892931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811625089.5A Expired - Fee Related CN109847946B (en) | 2018-12-28 | 2018-12-28 | Application of medicament in flotation decalcification of magnesite |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109847946B (en) |
| WO (1) | WO2020133557A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302904B (en) * | 2019-06-28 | 2021-02-02 | 武汉理工大学 | Calcium-reducing purification method for high-grade basic magnesium carbonate ore |
| CN110575911A (en) * | 2019-10-22 | 2019-12-17 | 湖北富邦新材料有限公司 | High-calcium magnesite flotation collector |
| CN111036416B (en) * | 2019-11-28 | 2021-11-16 | 东北大学 | Application of efficient inhibitor 5' -ATP-2Na in magnesite direct flotation decalcification |
| CN111036414A (en) * | 2019-11-28 | 2020-04-21 | 东北大学 | Method for flotation decalcification of magnesite by using inhibitor STPP |
| CN111036415B (en) * | 2019-11-28 | 2021-11-16 | 东北大学 | Application of inhibitor HEDP in magnesite direct flotation decalcification |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1632499A1 (en) * | 1989-01-18 | 1991-03-07 | Научно-Исследовательский И Проектный Институт Обогащения И Механической Обработки Полезных Ископаемых "Уралмеханобр" | Method flotation of magnesite ores |
| CN102189040B (en) * | 2011-01-26 | 2013-04-03 | 丹东市镁宝镁业有限公司 | Method for carrying out flotation on high-silicon high-calcium low-grade magnesite step by step |
| CN103272702B (en) * | 2013-06-08 | 2015-01-07 | 北京矿冶研究总院 | Flotation collector and method for obtaining high-grade magnesite concentrate from low-grade magnesite |
| CN103951701B (en) * | 2014-04-15 | 2015-12-09 | 中南大学 | A kind of aminophosphonic acid compounds and methods for making and using same thereof |
| CN104399593B (en) * | 2014-10-20 | 2017-02-15 | 辽宁科技大学 | Magnesite ore desilicication and decalcification method |
| CN104384027A (en) * | 2014-11-05 | 2015-03-04 | 北方重工集团有限公司 | Vertical roll final flour mill flotation method for magnesite ores |
| CN104437883B (en) * | 2014-11-13 | 2017-04-05 | 中蓝连海设计研究院 | Process the digestion desliming reverse flotation method of low grade high-silicon high calcium magnesite |
| CN107774454A (en) * | 2016-08-26 | 2018-03-09 | 陈淑芳 | A kind of method for floating of high calcium magnesite |
| CN106345616A (en) * | 2016-11-28 | 2017-01-25 | 肃北镁科技耐火材料有限责任公司 | Flotation calcium-removing agent and method for magnesite |
| CN107413514B (en) * | 2017-06-19 | 2019-03-15 | 中冶北方（大连）工程技术有限公司 | A kind of high-silicon high calcium magnesite low cost ore-dressing technique |
-
2018
- 2018-12-28 CN CN201811625089.5A patent/CN109847946B/en not_active Expired - Fee Related
-
2019
- 2019-01-03 WO PCT/CN2019/070183 patent/WO2020133557A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020133557A1 (en) | 2020-07-02 |
| CN109847946A (en) | 2019-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109847946B (en) | Application of medicament in flotation decalcification of magnesite | |
| CN109847947B (en) | Method for flotation decalcification of magnesite by EGTA and SHMP synergistic inhibition | |
| CN104831065B (en) | Manganese cobalt high is than method that nickel cobalt in nickel cobalt manganese raw material with manganese separate | |
| CN110237937B (en) | Test method for realizing magnesite single-step reverse flotation desilication and decalcification | |
| WO2020220380A1 (en) | Method for decalcification of magnesitewith reverse flotation by using eddha inhibitor | |
| CN104525384B (en) | Preparation method of inhibitor of limonite | |
| CN109622232B (en) | Method for flotation decalcification of magnesite by temperature control | |
| CN103691574B (en) | A kind of preparation method of dolomite inhibitor and application thereof | |
| CN111036415B (en) | Application of inhibitor HEDP in magnesite direct flotation decalcification | |
| CN111036411B (en) | Application of inhibitor acrylic acid maleic acid copolymer sodium salt in flotation and demagging of phosphate ore | |
| CN109082537B (en) | Comprehensive utilization method of roasted gold concentrate | |
| CN110899000B (en) | Application of combined collecting agent for magnesite flotation decalcification | |
| CN101857256B (en) | Method for removing silicon dioxide from low-grade diasporite type bauxite | |
| CN111359782A (en) | Combined flotation reagent for inhibiting magnesium-containing silicate gangue minerals | |
| CN111036413B (en) | Application of inhibitor AA/AMPS in positive flotation and magnesium removal of phosphate ore | |
| CN111036416B (en) | Application of efficient inhibitor 5' -ATP-2Na in magnesite direct flotation decalcification | |
| CN111715408B (en) | Flotation reagent for flotation of fluorite in scheelite and flotation method thereof | |
| WO2015042735A1 (en) | Combined adjusting agent for flotation of calcite-type gangue phosphorus ore and use method thereof | |
| CN111036412B (en) | Application of inhibitor HPMA in positive flotation and magnesium removal of phosphate ore | |
| CN105127008A (en) | Method for preparing stibnite inhibitor | |
| CN112138873B (en) | Application of selective inhibitor EDTMPS in flotation and desilication of magnesite | |
| CN108380377B (en) | Method for improving yield of reverse flotation iron ore concentrate and reducing caustic soda consumption | |
| CN112604815A (en) | Application of dihydric phosphate in synchronous reverse flotation desilication and decalcification of magnesite | |
| CN115646657A (en) | Scheelite and calcium-containing gangue separation inhibitor and application thereof | |
| CN115537560A (en) | Lead and silver leaching combined agent for zinc leaching residues and application method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191224 Termination date: 20211228 |